Read more
Informationen zum Autor Jens Kurreck is professor for nucleic acids technologies at the University of Stuttgart (Germany). He received his PhD at the Technical University Berlin in 1998 and was a postdoc at the Arizona State University in Tempe, USA. From 1999 to 2007 he was assistant professor ('Habilitand') at the Free University Berlin. Furthermore, he holds a master's degree in philosophy. His group has been working in the field of gene silencing for many years with a focus on pain research and heart muscle infections. In 2005, Jens Kurreck received the award for the best teaching at the biochemistry department as well as the Young Scientist Lectureship Award of the European Society for Neurochemistry (ESN). Klappentext Oligonucleotides are a promising new class of biomacromolecules for various therapeutic purposes to treat cancer, viral infections and inflammatory diseases. Antisense oligonucleotides against the cytomegalovirus and an aptamer to treat an ocular disease have already been approved by the regulatory authorities. A number of additional oligonucleotides including small interfering RNAs are currently in various phases of clinical development. Therapeutic Oligonucleotides provides a comprehensive overview of the development of oligonucleotides for therapeutic applications, touching on a number of different strategies with a special focus on the latest progress in the field of RNA interference. The book covers a wide range of topics: antisense oligonucleotides, small interfering and short hairpin RNAs, decoy and immune stimulatory oligonucleotides and aptamers as well as delivery of oligonucleotides. Written by experts in the field, both academic and industrial, Therapeutic Oligonucleotides provides a compelling overall update on current status of research and clinical development and will also serve as a valid resource for researchers and students as well as academics, consultants and scientists. Zusammenfassung This book provides a compelling overall update on current status of RNA interference Inhaltsverzeichnis Chapter 1: The Role of Backbone Modifications in Oligonucleotide-Based Strategies; Chapter 2: Genasense (G3139): An Antisense Bcl-2 Oligodeoxyribonucleotide with Substantial Clinical Activity and a Complex Mechanism of Action; Chapter 3: Antisense Morpholino Oligomers and Their Peptide Conjugates; Chapter 4: Peptide-PNA Conjugates for Modulation of Gene Expression; Chapter 5: Locked Nucleic Acid: Properties & Therapeutic Aspects; Chapter 6: Immune Stimulatory Oligonucleotides; Chapter 7: Decoy Oligonucleotides to Treat Inflammatory Diseases; Chapter 8: AS1411: Development of an Anticancer Aptamer; Chapter 9: Spielgelmer NOX-E36 for Renal Diseases; Chapter 10: Strategies for the Delivery of Oligonucleotides In Vivo; Chapter 11: Lipid-Mediated in vivo Delivery of Small Interfering RNAs; Chapter 12: Vector-Mediated and Viral Delivery of Short Hairpin RNAs; Chapter 13: Development of an RNAi Based Gene Therapy against HIV-1; Chapter 14: RNA Based Therapies for Treatment of HIV Infection...
